Med-IQ
Uterine Fibroids: Spotlight on Care Disparities and the Role of GnRH Antagonist Combinations in Treatment

Uterine Fibroids: Spotlight on Care Disparities and the Role of GnRH Antagonist Combinations in Treatment

Webcast
Online Course | Specialties: Women's Health
Released: 12/16/2021
|
Expires: 12/15/2022
|
Max Credits: 0.75
Jump to Education

Faculty
Erica E. Marsh, MD, MSCI, FACOG
S. Jan Behrman Collegiate Professor of Reproductive Medicine
Chief of the Division of Reproductive Endocrinology and Infertility
Professor, Department of Obstetrics and Gynecology
University of Michigan Medical School
Ann Arbor, MI

Elizabeth A. Stewart, MD 
Fellowship Director, Division of Reproductive Endocrinology and Infertility 
Professor, Department of Obstetrics and Gynecology  
Professor, Department of Surgery  
Mayo Clinic Alix School of Medicine 
Rochester, MN

Activity Planners
Julie Blum, PhD
Director, Clinical Content
Med-IQ
Baltimore, MD

Samantha Gordon, MS
Accreditation Manager
Med-IQ
Baltimore, MD

Amy Sison
Director of CME
Med-IQ
Baltimore, MD

Learning Objectives
Upon completion, participants should be able to:

  • Describe the burden imposed by UF, the most recent clinical management guidelines, and current medical and surgical treatment options, as well as identify gaps and disparities in care
  • Apply information from recent clinical trials involving new GnRH antagonist combination therapies to clinical practice
  • Engage patients in productive shared decision-making conversations about management of UF that consider their individual preferences and goals

Target Audience
This activity is intended for obstetrician-gynecologists and other healthcare professionals involved in the care and treatment of patients with UF.

Statement of Need
An estimated 26 million women aged 15 to 50 years have uterine fibroids (UF), and many other women may be undiagnosed. Unfortunately, many women are unaware of UF as a diagnosis or do not seek care for their symptoms, and about 1 in 5 believe that hysterectomy is the only treatment option. UF are more prevalent in women of color; indeed, 70% to 80% of Black women develop UF by their late 40s. In addition, Black women tend to be younger at UF onset, have larger and more numerous tumors, and are more likely to undergo surgical interventions for UF than other women. Clinicians must be aware of such disparities in care and gaps in patient awareness to be able to identify patients who have a high risk of UF, understand the full burden of disease, and properly educate women about the disease and available treatment options, with the goal of helping patients obtain treatment that improves their symptoms and quality of life in a way that aligns with their individual goals and preferences.

Providership Statement
Provided by Med-IQ.

Accreditation/Designation Statements
Med-IQ is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.

Med-IQ designates this enduring material for a maximum of 0.75 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Instructions to Receive Credit
To receive credit, read the introductory CME material, watch the webcast, and complete the evaluation, attestation, and post-test, answering at least 70% of the post-test questions correctly.

Initial Release Date: December 16, 2021
Expiration Date: December 15, 2022
Estimated Time to Complete This Activity: 45 minutes

Disclosure Policy
Med-IQ requires any person in a position to control the content of an educational activity to disclose all relevant financial relationships with any commercial interest. The ACCME defines “relevant financial relationships” as those in any amount occurring within the past 24 months that could create a conflict of interest (COI). Individuals who refuse to disclose will not be permitted to contribute to this CME activity in any way. Med-IQ has policies in place that will identify and resolve COIs prior to this educational activity. Med-IQ also requires faculty to disclose discussions of investigational products or unlabeled/unapproved uses of drugs or devices regulated by the US Food and Drug Administration.

Drug/Product Usage by Faculty
Off-label/unapproved drug uses or products are mentioned within this activity.

Disclosure Statement
The content of this activity has been peer reviewed and has been approved for compliance. The faculty and contributors have indicated the following financial relationships, which have been resolved through an established COI resolution process, and have stated that these reported relationships will not have any impact on their ability to give an unbiased presentation. 
 
Erica E. Marsh, MD, MSCI, FACOG
Consulting fees/advisory boards: Myovant Sciences Ltd., Pfizer, Inc.

Elizabeth A. Stewart, MD 
Royalty: Massachusetts Medical Society, UpToDate
Consulting fees/advisory boards: AbbVie Inc., Bayer HealthCare Pharmaceuticals, Myovant Sciences Ltd., ObsEva

The peer reviewers and other activity planners have no financial relationships to disclose.
 
Statement of Evidence-Based Content
Educational activities that assist physicians in carrying out their professional responsibilities more effectively and efficiently are consistent with the ACCME definition of continuing medical education (CME). As an ACCME-accredited provider of CME, Med-IQ has a policy to review and ensure that all the content and any recommendations, treatments, and manners of practicing medicine in CME activities are scientifically based, valid, and relevant to the practice of medicine. Med-IQ is responsible for validating the content of the CME activities it provides. Specifically, (1) all recommendations addressing the medical care of patients must be based on evidence that is scientifically sound and recognized as such within the profession; (2) all scientific research referred to, reported, or used in CME in support or justification of a patient care recommendation must conform to generally accepted standards of experimental design, data collection, and analysis.

Med-IQ is not liable for any decision made or action taken in reliance upon the information provided through this activity.
 
Contact Information
For questions or comments about this activity, please contact Med-IQ. Call (toll-free) 866 858 7434 or email info@med-iq.com.

System Requirements

Desktop

Mobile

  • Operating system - Med-IQ supports the current operating system, plus two prior releases:
    • Android (eg, Samsung Galaxy)
    • Apple (eg, iPhone/iPad)
  • Browsers - Med-IQ supports the default browser for the applicable operating system release, plus two prior releases:
    • Android (Chrome)
    • Apple (Safari)

Applications & Software

For technical assistance, please refer to our Support Manual.

Disclaimer
The information provided through this activity is for continuing education purposes only and is not meant to substitute for the independent medical judgment of a physician relative to diagnostic and treatment options of a specific patient’s medical condition.

Privacy & Confidentiality
Med-IQ is committed to honoring your privacy and protecting any personal information you choose to share with us. For detailed information about our privacy policy, please visit: www.med-iq.com/privacy-notice.

Complimentary CE
This activity is available free of charge to participants.

Acknowledgment of Commercial Support
This activity is supported by an educational grant from Pfizer, Inc. and Myovant Sciences Ltd.
 
Copyrighted

Abstract

Here are the key takeaways from this activity. Deeper insights and evidence, plus an opportunity to receive credit, are available at the "Continue" button below.

  • Approximately 30% to 50% of women with UF present with clinical symptoms; these symptoms vary with location and size of the fibroid
  • Black women have more severe disease than White women; social determinants of health, lifestyle factors, environmental exposures, and genetic variations may all contribute to disparities in fibroid prevalence and incidence
  • Oral GnRH antagonists elagolix and relugolix have been shown to have good efficacy and safety profiles when used to treat patients with UF

View reference list.

Click “Continue” to proceed through this activity and/or receive credit. To receive credit and a certificate, you must complete all of the chapters in this activity.

By clicking "Continue," you confirm that you have reviewed the CME information.

Continue

Unless otherwise indicated, photographed subjects who appear within the content of this activity or on artwork associated with this activity are models; they are not actual patients or doctors.

The information provided through this activity is for continuing education purposes only and is not meant to substitute for the independent medical judgment of a physician relative to diagnostic and treatment options of a specific patient’s medical condition.

COPYRIGHTED. Republication or redistribution of Med‑IQ content, including by framing, is prohibited without prior written consent. Med‑IQ shall not be liable for any errors or delays in the content, or for any actions taken in reliance thereon.